Arch Venture Fund X, L.p. - Net Worth and Insider Trading

Arch Venture Fund X, L.p. Net Worth

The estimated net worth of Arch Venture Fund X, L.p. is at least $293 Million dollars as of 2024-06-06. Arch Venture Fund X, L.p. is the 10% Owner of Neumora Therapeutics Inc and owns about 29,545,420 shares of Neumora Therapeutics Inc (NMRA) stock worth over $293 Million. Details can be seen in Arch Venture Fund X, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Arch Venture Fund X, L.p. has not made any transactions after 2023-09-19 and currently still holds the listed stock(s).

Transaction Summary of Arch Venture Fund X, L.p.

To

Arch Venture Fund X, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Arch Venture Fund X, L.p. owns 5 companies in total, including Erasca Inc (ERAS) , Sana Biotechnology Inc (SANA) , and Verve Therapeutics Inc (VERV) among others .

Click here to see the complete history of Arch Venture Fund X, L.p.’s form 4 insider trades.

Insider Ownership Summary of Arch Venture Fund X, L.p.

Ticker Comapny Transaction Date Type of Owner
ERAS Erasca Inc 2021-07-15 10 percent owner
SANA Sana Biotechnology Inc 2021-02-03 10 percent owner
VERV Verve Therapeutics Inc 2021-06-16 10 percent owner
LIMIT LIMIT 2022-10-19 10 percent owner
LIMIT LIMIT 2023-09-19 10 percent owner

Arch Venture Fund X, L.p. Latest Holdings Summary

Arch Venture Fund X, L.p. currently owns a total of 1 stock. Arch Venture Fund X, L.p. owns 29,545,420 shares of Neumora Therapeutics Inc (NMRA) as of September 19, 2023, with a value of $293 Million.

Latest Holdings of Arch Venture Fund X, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NMRA Neumora Therapeutics Inc 2023-09-19 29,545,420 9.93 293,386,021

Holding Weightings of Arch Venture Fund X, L.p.


Arch Venture Fund X, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Arch Venture Fund X, L.p. has made a total of 1 transactions in Neumora Therapeutics Inc (NMRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Neumora Therapeutics Inc is the acquisition of 1,500,000 shares on September 19, 2023, which cost Arch Venture Fund X, L.p. around $26 Million.

Insider Trading History of Arch Venture Fund X, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Arch Venture Fund X, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Arch Venture Fund X, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arch Venture Fund X, L.p. is 21.45%. GuruFocus also compares Arch Venture Fund X, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Arch Venture Fund X, L.p. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Arch Venture Fund X, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Arch Venture Fund X, L.p.

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -17.28 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -13.55 LIMIT LIMIT LIMIT LIMIT LIMIT

Arch Venture Fund X, L.p. Ownership Network

Ownership Network List of Arch Venture Fund X, L.p.

No Data

Ownership Network Relation of Arch Venture Fund X, L.p.

Insider Network Chart

Arch Venture Fund X, L.p. Owned Company Details

What does Erasca Inc do?

Who are the key executives at Erasca Inc?

Arch Venture Fund X, L.p. is the 10 percent owner of Erasca Inc. Other key executives at Erasca Inc include director & 10 percent owner & See Remarks Jonathan E Lim , Chief Medical Officer Shannon Morris , and General Counsel Ebun Garner .

Erasca Inc (ERAS) Insider Trades Summary

Over the past 18 months, Arch Venture Fund X, L.p. made no insider transaction in Erasca Inc (ERAS). Other recent insider transactions involving Erasca Inc (ERAS) include a net purchase of 2,300,000 shares made by Jonathan E Lim , a net purchase of 150,000 shares made by Alexander W. Casdin , and a net purchase of 615,384 shares made by Bihua Chen .

In summary, during the past 3 months, insiders sold 0 shares of Erasca Inc (ERAS) in total and bought 80,000 shares, with a net purchase of 80,000 shares. During the past 18 months, 0 shares of Erasca Inc (ERAS) were sold and 3,105,384 shares were bought by its insiders, resulting in a net purchase of 3,105,384 shares.

Erasca Inc (ERAS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Erasca Inc Insider Transactions

No Available Data

Arch Venture Fund X, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Arch Venture Fund X, L.p.. You might contact Arch Venture Fund X, L.p. via mailing address: 8755 W. Higgins Road, Suite 1025, Chicago Il 60631.

Discussions on Arch Venture Fund X, L.p.

No discussions yet.